Table 2 Parasitological and clinical outcomes among patients treated for uncomplicated P. falciparum malaria with either artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL) in 2012–2013 on three sites in Togo
Drug | Site | n | Non-PCR-corrected | PCR-corrected | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Excl/loss | ACPR, n (%) | LCF | LPF | TF (%) | (95 % CI) | Excl/loss | ACPR, n (%) | LCF | LPF | TF (%) | (95 % CI) | Kaplan–Meier | AE (%) | |||
ASAQ | Lomé | 93 | 0 | 91 (97.8) | 0 | 2 | 2 (2.2) | (0.3–7.6) | 2 | 91 (100) | 0 | 0 | 0 (0.0) | (0.0–4.0) | 0.0 (0.00–0.00) | 1 (1.0) |
ASAQ | Sokodé | 86 | 3 | 81 (97.6) | 1 | 1 | 2 (2.4) | (0.3–8.4) | 5 | 81 (100) | 0 | 0 | 0 (0.0) | (0.0–4.5) | 0.0 (0.00–0.00) | 2 (2.3) |
ASAQ | Niamtougou | 83 | 0 | 77 (92.8) | 0 | 6 | 6 (7.2) | (2.7–15.1) | 3 | 77 (96.3) | 0 | 3 | 3 (3.8) | (0.8–10.6) | 0.03 (0.01–0.10) | 1 (1.2) |
ASAQ | Overall | 262 | 3 | 249 (96.1) | 1 | 9 | 10 (3.9) | (1.9–7.0) | 10 | 249 (98.8) | 0 | 3 | 3 (1.2) | (0.2–3.4) | 1.2 (0. 4–3.6) | 4 (1.5) |
AL | Lomé | 90 | 3 | 83 (95.4) | 1 | 3 | 4 (4.6) | (1.3–11.4) | 7 | 83 (100) | 0 | 0 | 0 (0.0) | (0.0–4.3) | 0.00 (0.00–0.00) | 0 (0.0) |
AL | Sokodé | 88 | 6 | 72 (87.8) | 3 | 7 | 10 (12.2) | (6.0–21.3) | 14 | 72 (97.3) | 0 | 2 | 2 (2.7) | (0.3–9.4) | 0.03 (0.01–0.10) | 3 (3.4) |
AL | Niamtougou | 83 | 7 | 65 (85.5) | 1 | 10 | 11 (14.5) | (7.5–14.5) | 16 | 65 (97.0) | 0 | 2 | 2 (3.0) | (0.4–10.4) | 0.03 (0.01–0.10) | 4 (4.8) |
AL | Overall | 261 | 16 | 220 (89.8) | 5 | 20 | 25 (10.2) | (4.7–6.7) | 37 | 220 (98.2) | 0 | 4 | 4 (1.8) | (0.5–4.5) | 1.7 (0.6–4.4) | 7 (2.7) |